Michael Elliott

Michael Elliott leads clinical operations. He has over two decades of experience in clinical trial management, spanning Phase 1 through pivotal Phase 3 trials, in over 20 countries. Mr. Elliott has managed over 60 company-sponsored clinical trials and almost a dozen investigator-sponsored trials. Before joining Carmot, Michael was Senior Director, Clinical Development at NGM Biopharmaceuticals. In this role, he built and led the clinical operations group for NGM, which had multiple programs studying first-in-class, first-in-human product candidates. Previously, he was Director, Clinical Operations at Afferent Pharmaceuticals, a company that was acquired by Merck. Prior to Afferent, he was Director, Clinical Operations at Anthera Pharmaceuticals where he led the clinical operations department and supported the regulatory submission for a Special Protocol Assessment (SPA) with FDA. Michael earned a Bachelor of Arts from the University of Pittsburgh and a Master of Arts from Xavier University.